

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Roberto Angelo MOTTERLINI

Atty. Ref.: 620-371

Serial No. 10/535,508

Group: 1615

Filed: May 18, 2005

Examiner: Unknown

For: THERAPEUTIC DELIVERY OF CARBON MONOXIDE TO
EXTRACORPOREAL AND ISOLATED ORGANS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 12, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **N/C**
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **\$180.00**
- 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith;

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE		ATTY/DOCKET NO.	SERIAL NO.			
CITATION		620-371	10/535,508			
		APPLICANT				
		Roberto Angelo MOTTERLINI				
(Use several sheets if necessary)		FILED DATE	GROUP			
		May 18, 2005	1615			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE		
1	5,882,674	03/1999	Herrmann et al.			
FOREIGN PATENT DOCUMENTS						
			TRANSLATION			
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
2	WO 98/48848	11/1998	WIPO			
3	WO 91/01128	02/1991	WIPO			
4	WO 91/01301	02/1991	WIPO			
5	WO 98/29115	07/1998	WIPO			
6	HU-B-211 084	10/1995	Hungary			
7	WO 95/05814	03/1995	WIPO			
8	WO 00/56743	09/2000	WIPO			
52	2002/0155166	10/2002	Choi et al			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
9	Sjostrand T. Endogenous formation of carbon monoxide in man under normal and pathological conditions. Scan J Clin Lab Invest 1949;1:201-14.					
10	Coburn RF, Blakemore WS, Forster RE. Endogenous carbon monoxide production in man. J Clin Invest 1963;42:1172-8.					
11	Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969;244:6388-94.					
12	Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-68.					
13	Furchtgott RF, Jothianandan D. Endothelium-dependent and -independent vasodilation involving cGMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels 1991;28:52-61.					
14	Morita T, Perrella MA, Lee ME, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci USA 1995;92:1475-9.					
15	Sammut IA, Foresti R, Clark JE, Exon DJ, Vesely MJ, Sarathchandra P, Green CJ, Motterlini R. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Br J Pharmacol 1998;125:1437-44.					
16	Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37:517-54.					
17	Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RP, Choi AM, Poss KD, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nature Med 1998;4:1073-7.					
18	Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of inflammatory response. Nature Med 1996;2:87-90.					

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY/DOCKET NO.	SERIAL NO.			
CITATION		620-371	10/535,508			
		APPLICANT				
		Roberto Angelo MOTTERLINI				
(Use several sheets if necessary)		FILING DATE	GROUP			
		May 18, 2005	1615			
FOREIGN PATENT DOCUMENTS						
					TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
26	WO 02/080923	10/2002	WIPO			
27	WO 94/22482	10/1994	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

19	Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses <i>in vivo</i> . <i>Circ Res</i> 1998;83:568-77.
20	Otterbein LE, Mantell LL, Choi AMK. Carbon monoxide provides protection against hyperoxic lung injury. <i>Am J Physiol</i> 1999;276:L688-94.
21	Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AMK. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. <i>J Clin Invest</i> 1999;103:1047-54.
22	Herrick RS, Brown TL. Flash photolytic investigation of photoinduced carbon monoxide dissociation from dinuclear manganese carbonyl compounds. <i>Inorg Chem</i> 1984;23:4550-3.
23	Alessio E, Milani B, Bolle M, Mestroni G, Falechini P, Todone F, Geremia S, Calligaris M. Carbonyl derivatives of chloride-dimethyl sulfoxide-ruthenium(II) complexes: synthesis, structural characterization, and reactivity of Ru(CO)x(DMSO)-xCl2 complexes (x=1-3). <i>Inorg Chem</i> 1995;34:4722-34.
24	Sato K., Balla J., Otterbein L., Smith R.N., Brouard S., Lin Y., Csizmadia E., Sevigny J., Robson S.C., Vercellotti G., Choi A.M., Bach F.H., Soares M.P. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. <i>J Immunol.</i> 166:4185-4194, 2001.
25	G. Pneumatikakis, A. Yannopoulos and J. Markopoulos, <i>Inorg. Chim. Acta</i> , 1988, 151, 243.
28	Motterlini R. et al., Carbon monoxide-releasing molecules: characterization of biomedical and vascular activities, <i>Circulation Research</i> . 2002, vol. 90, no. 2, E17-E24.
29	Yan Y.K. et al., Cytotoxicity of rhenium (I) alkoxo and hydroxo carbonyl complexes in murin and human tumor cells, <i>Pharmazie</i> (2000), 55(4), 307-313.
30	Becker M.J. et al., Age related changes in antibody dependent cell mediated cytotoxicity in mouse spleen, <i>Israel J. Medical Sciences</i> (1979), vol. 15, no. 2, 147-150.
31	Nagai M. et al., Unusual CO bonding geometry in abnormal subunits of hemoglobin M Boston and hemoglobin M Saskatoon, <i>Biochemistry</i> (1991), vol. 30, no. 26, 6495-6503.
32	Tomita A. et al., Structure and reaction of bis(L-cysteinato)dicarbonyliron(II), <i>Inorganic and Nuclear Chemistry Letters</i> (1968), 4(12), 715-18.
33	Terrier, F.; Terzian, G.; Mossyan, J.; Benlian, D, FTIR spectrometric study of geometrical isomers of dicarbonyl ferrobliscysteinate Influence of the counter cation. Laboratoire de Chimie de Coordination, D22, Universite de Provence, Av. Escadrille Normandie-Niemen, Marseille, Fr. <i>J. Mol. Struct.</i> (1995), 344(3), 189-93. CODEN: JMOSB4 ISSN: 0022-2860. Journal written in English. CAN 122:250765 AN 1995:414110 CAPLUS (Copyright 2002 ACS)
34	Szakacs-Schmidt, Aniko; Kreisz, Jozsef; Marko, Laszlo; Nagy-Magos, Zsuzsa; Takacs, Janos, Iron(II) thiolates as reversible carbon monoxide carriers, <i>Res. Inst. Chem. Eng., Hung. Acad. Sci., Veszprem, Hung. Inorg. Chim. Acta</i> (1992), 198-200 401-5. CODEN: ICHAA3 ISSN: 0020-1693. Journal written in English. CAN 117:263637 AN 1992:663637 CAPLUS (Copyright 2002 ACS)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application

Form PTO-FB-A820 (Also PTO-1449)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

